NASDAQ:CALT Calliditas Therapeutics AB (publ) (CALT) Stock Price, News & Analysis $40.00 0.00 (0.00%) As of 07/24/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About Calliditas Therapeutics AB (publ) Stock (NASDAQ:CALT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CALT alerts:Sign Up Key Stats Today's Range$40.00▼$40.0050-Day Range$40.00▼$40.0052-Week Range$15.25▼$43.00VolumeN/AAverage Volume10,339 shsMarket Capitalization$1.19 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden. Read More Receive CALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Calliditas Therapeutics AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Email Address CALT Stock News HeadlinesCalliditas Therapeutics to Present Four Abstracts at American Society of Nephrology (ASN) Kidney Week 2024October 17, 2024 | tmcnet.comCalliditas Therapeutics (NASDAQ:CALT) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.com[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.July 25 at 2:00 AM | Golden Portfolio (Ad)Delisting of Calliditas Therapeutics AB (publ) from Nasdaq StockholmSeptember 16, 2024 | prnewswire.comNotice of extraordinary meeting of Calliditas Therapeutics AB (publ)September 3, 2024 | prnewswire.comCalliditas Therapeutics takes certain corporate actions following announcement by Asahi KaseiSeptember 3, 2024 | prnewswire.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | msn.comCalliditas Therapeutics AB (publ) (CALT) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | seekingalpha.comSee More Headlines CALT Stock Analysis - Frequently Asked Questions How have CALT shares performed this year? Calliditas Therapeutics AB (publ)'s stock was trading at $40.0001 at the beginning of 2025. Since then, CALT stock has increased by 0.0% and is now trading at $40.0001. How were Calliditas Therapeutics AB (publ)'s earnings last quarter? Calliditas Therapeutics AB (publ) (NASDAQ:CALT) announced its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.09. The company earned $52.36 million during the quarter, compared to analysts' expectations of $42.89 million. Calliditas Therapeutics AB (publ) had a negative net margin of 30.18% and a negative trailing twelve-month return on equity of 212.04%. Read the conference call transcript. When did Calliditas Therapeutics AB (publ) IPO? Calliditas Therapeutics AB (publ) (CALT) raised $179 million in an initial public offering (IPO) on Friday, June 5th 2020. The company issued 9,200,000 shares at a price of $19.50 per share. Citigroup, Jefferies and Stifel served as the underwriters for the IPO and Carnegie was co-manager. How do I buy shares of Calliditas Therapeutics AB (publ)? Shares of CALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Calliditas Therapeutics AB (publ) own? Based on aggregate information from My MarketBeat watchlists, some other companies that Calliditas Therapeutics AB (publ) investors own include Advanced Micro Devices (AMD), Celsius (CELH), NIO (NIO), NVIDIA (NVDA), Reata Pharmaceuticals (RETA), Target (TGT) and Athenex (ATNX). Company Calendar Last Earnings8/13/2024Today7/25/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CALT CIK1795579 Webwww.calliditas.se Phone46-0-841-130-05FaxN/AEmployees180Year Founded2004Profitability EPS (Trailing Twelve Months)($1.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$43.96 million Net Margins-30.18% Pretax Margin-29.40% Return on Equity-212.04% Return on Assets-27.96% Debt Debt-to-Equity Ratio9.44 Current Ratio2.69 Quick Ratio2.59 Sales & Book Value Annual Sales$1.60 billion Price / Sales0.74 Cash FlowN/A Price / Cash FlowN/A Book Value$1.06 per share Price / Book37.74Miscellaneous Outstanding Shares29,790,000Free Float29,135,000Market Cap$1.19 billion OptionableOptionable Beta1.77 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:CALT) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Calliditas Therapeutics AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.